Financial Tear Sheet

Corporate Profile

Galectin Therapeutics is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. The Company's drug candidates are based on unique carbohydrate technology to target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. The Company is pursuing a clear development pathway to clinical enhancement and commercialization for lead compounds in liver fibrosis and cancer immunotherapy.

Primary IR Contact

Harold H. Shlevin, Ph.D.
Chief Operating Officer
Galectin Therapeutics, Inc.
Phone: 678-615-3213
E-mail:
shlevin@galectintherapeutics.com

Stock Performance

GALT (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	**$4.18**
Change (%)	▼ 0.24 (5.43%)
Volume	53,682
52 Week Low	$1.60
Market Cap	$67,929,180
Rolling EPS	-0.77
PE Ratio	N/A
Shares Outstanding	16,251,000

Data as of 05/22/13 4:00 p.m. ET

Recent Headlines & Events

05/15/13 - 8:00 a.m.
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders

05/10/13 - 4:00 p.m.
Galectin Therapeutics Reports First Quarter 2013 Financial Results

04/29/13 - 8:00 a.m.
Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies

Date	Title
05/23/13 9:30 a.m. ET	**Galectin Therapeutics Results of Shareholders Meeting Conference Call**

SEC Filings

Filing Date	Form
05/15/13	8-K
05/10/13	8-K
05/10/13	10-Q
05/01/13	4

Corporate Governance

Rod D. Martin

Gilbert F. Amelio, Ph.D.

Arthur R. Greenberg

Jerald K. Rome

Steven Prelack

S. Colin Neill

Powered By EDGAR Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.